15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Abcellera Biologics Inc, 4 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $4.00 to $11.00 (about 2.8x), a sign of real disagreement on valuation. The average target of $8.00 sits 51% above the current $5.29. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near -57% this year and -3% next, consensus EPS building from about $-0.17 next quarter toward $-0.70 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy480%
Hold120%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Abcellera Biologics Inc.
As of Jul, 4 of 5 firms rate ABCL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ABCL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.19 – $-0.17 · 4 analysts · -8% YoY
Next period, 4 analysts expect Abcellera Biologics Inc to earn $-0.17 a share (range $-0.19 – $-0.17), versus $-0.19 a year earlier. Full-year consensus is $-0.63, growing to $-0.70 the year after.
REVENUE · NEXT QUARTER
$7.7M
Range $5.7M – $10.1M · 4 analysts · -14% YoY
Revenue is expected to reach $7.7M (range $5.7M – $10.1M), -14.0% year-over-year. Full-year consensus is $31.6M, rising to $34.1M next year.
Top analysts covering Abcellera Biologics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABCL.
#1
RW
Robert Wasserman
Benchmark · Rank #259
Buy
$11.00+107.7% to target
Overall win rate
39%
+ Follow
#2
Scott Schoenhaus
Keybanc · Rank #345
Buy
$10.00+88.9% to target
Overall win rate
29%
+ Follow
#3
SW
Stephen Willey
Stifel
Buy
$8.00+51.1% to target
Coverage
—
+ Follow
#4
FK
Faisal Khurshid
Leerink Partners
Hold
$4.00-24.5% to target
Coverage
—
+ Follow
#5
BS
Brendan Smith
TD Cowen
Buy
No targeton ABCL
Coverage
—
+ Follow
ABCL stock forecast FAQ
What is ABCL's average 12-month price target?+
The 5 analysts with a live target average $8.00 for Abcellera Biologics Inc over the next 12 months, ranging from a $11.00 high to a $4.00 low.
Is ABCL stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 4 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ABCL?+
The Street-high target is $11.00 (Benchmark), and the Street-low is $4.00 (Leerink Partners). The average of all 5 active targets is $8.00.
How many Wall Street analysts cover ABCL?+
5 analysts have an active rating on Abcellera Biologics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering ABCL?+
Among analysts who currently cover ABCL, Robert Wasserman of Benchmark has the strongest overall Quantellect track record (Rank #259). Their current call is Buy with a $11.00 target.
What is Abcellera Biologics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.19 – $-0.17) across 4 analysts. Full-year EPS is projected at $-0.63, rising to $-0.70 the following year.
How much revenue is Abcellera Biologics Inc expected to report next quarter?+
Consensus revenue is $7.7M (range $5.7M – $10.1M). Full-year revenue is projected at $31.6M, growing to $34.1M next year.
Have analysts been upgrading or downgrading ABCL lately?+
As of Jul, 4 of 5 firms rate ABCL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABCL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
